We are live on
!
Find out more
Corvus Pharmaceuticals
CRVS
CRVS
54 hedge funds and large institutions have $180M invested in Corvus Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
62% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 13
0% more funds holding
Funds holding: 54 → 54 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
0.99% less ownership
Funds ownership: 83.78% → 82.79% (-0.99%)
35% less capital invested
Capital invested by funds: $280M → $180M (-$99.3M)
Holders
54
Holders Change
–
Holders Change %
0%
% of All Funds
1.22%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
8
Increased
21
Reduced
13
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.39M |
| 2 |
BlackRock
New York
|
+$3.7M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$527K |
| 4 |
Renaissance Technologies
New York
|
+$511K |
| 5 |
Millennium Management
New York
|
+$487K |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$5.45M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.11M |
| 4 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$1.19M |
| 5 |
JP Morgan Chase
New York
|
-$906K |
